Shifting U.S. Vaccine Policy: Explaining Federal Actions and Exploring Public Opinion

Why It Matters

The policy shift reshapes vaccine access and mandates across the nation, potentially lowering immunization rates and increasing public‑health risk while creating a patchwork of state‑level standards.

Key Takeaways

• Federal vaccine schedule cut routine vaccines from 13 to 7.
• Six childhood vaccines shifted to shared decision‑making model.
• Over 25 states now diverge from CDC recommendations.
• Private insurers pledge coverage through 2026 despite schedule changes.
• Non‑medical school exemption rates rising, signaling growing vaccine hesitancy.

Summary

The briefing examined the Trump‑era overhaul of U.S. vaccine policy, highlighting the federal government’s recent decision to trim the pediatric schedule from 13 routine vaccines to just seven and to reclassify six vaccines—including COVID‑19, influenza and rotavirus—under a shared clinical decision‑making framework.

Key data points show that the new schedule reduces diseases targeted from 17 to 11, moves six vaccines out of the universal category, and prompts the HHS memo citing alignment with peer nations—though the U.S. remains an outlier. States have reacted sharply: more than 25 have announced they will no longer follow CDC/ACIP guidance, forming regional health alliances, while some Republican‑led legislatures propose eliminating school mandates. Private insurers have publicly committed to covering all previously recommended vaccines at no cost through 2026, and manufacturers signal reduced R&D investment amid policy uncertainty.

Notable examples include Secretary Robert F. Kennedy Jr.’s reconstitution of ACIP, the American Academy of Pediatrics’ lawsuit challenging the schedule changes, and a steady rise in non‑medical school exemption rates, which have increased since the 2019‑2020 school year. The briefing also cited the shift toward “parental choice” as a stated rationale for the policy shift.

The implications are profound: divergent state policies could fragment national immunization coverage, legal battles may delay implementation, and growing exemption trends risk eroding herd immunity. Insurers’ coverage pledges may cushion short‑term access, but long‑term public‑health outcomes hinge on how quickly states and the federal government reconcile these competing approaches.

Original Description

The U.S. Department of Health & Human Services (HHS) and the Center for Disease Control’s (CDC) Advisory Committee on Immunization Practices (ACIP) are expected to further review childhood and adult vaccination recommendations, potentially adding significant changes to those already made. To provide context, KFF held an hour-long virtual event on February 19, 2026, to discuss these developments and, based on recent KFF polling, the public’s views.

KFF experts shared insights on what this shifting policy environment means for state governments, the U.S. public health system, and Americans.